A Phase 1 interventional study of Doravirine and Placebo in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve, HIV-1-infected participants.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
Drug: Doravirine · Drug: Placebo
Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
Drug: Doravirine · Drug: Placebo
Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
Drug: Doravirine · Drug: Placebo
Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
Also known as: MK-1439
Placebo tablets once daily for 7 days.
Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load
The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval \<-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.
Time frame: Baseline and Day 7
Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7
The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.
Time frame: Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7
Maximum Plasma Concentration (Cmax) of Doravirine on Day 7
The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.
Time frame: Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7
Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7
The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.
Time frame: 24 hours postdose on Day 7 (Day 8)
Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7
The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.
Time frame: Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7
Participants with human immunodeficiency virus type 1 (HIV-1) who were antiretroviral therapy (ART)-naïve were enrolled at a single study center in Germany.
| Milestone | Doravirine 25 mg | Doravirine 200 mg | Placebo |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval \<-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.
| Percentage change | Doravirine 25 mg | Doravirine 200 mg | Placebo |
|---|---|---|---|
| Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load | -1.52 (-1.71 to -1.32) | -1.41 (-1.61 to -1.21) | -0.15 (-0.35 to 0.06) |
The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.
| uM*hr | Doravirine 25 mg | Doravirine 200 mg |
|---|---|---|
| Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7 | 11.2 (9.35 to 13.4) | 62.2 (52.0 to 74.4) |
The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.
| nM | Doravirine 25 mg | Doravirine 200 mg |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Doravirine on Day 7 | 826 (727 to 938) | 4300 (3790 to 4890) |
The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.
| nM | Doravirine 25 mg | Doravirine 200 mg |
|---|---|---|
| Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7 | 251 (188 to 335) | 1540 (1150 to 2060) |
The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.
| Hours | Doravirine 25 mg | Doravirine 200 mg |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7 | 1.00 (1.00 to 2.00) | 2.00 (1.00 to 4.00) |
Collected over Up to 14 days after the last dose of study drug (up to 21 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doravirine 25 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Doravirine 200 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Poststudy | 0/18 (0%) | 1/18 (5.6%) | 1/18 (5.6%) |
| Event | Doravirine 25 mg | Doravirine 200 mg | Placebo | Poststudy |
|---|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/6 | 0/6 | 0/6 | 1/18 |
| Event | Doravirine 25 mg | Doravirine 200 mg | Placebo | Poststudy |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/6 | 2/6 | 0/6 | 0/18 |
| HeadacheNervous system disorders | 0/6 | 2/6 | 2/6 | 0/18 |
| PalpitationsCardiac disorders | 0/6 | 1/6 | 0/6 | 0/18 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/18 |
| NauseaGastrointestinal disorders | 1/6 | 1/6 | 0/6 | 0/18 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/18 |
| Oral herpesInfections and infestations | 0/6 | 1/6 | 0/6 | 0/18 |
| TonsilitisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/18 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/6 | 0/6 | 0/18 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 0/6 | 0/6 | 0/18 |
| Age, Continuous(Years) | Doravirine 25 mg | Doravirine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 36.7 ± 5.8 | 34.8 ± 8.4 | 26.8 ± 1.0 | 32.8 ± 7.1 |
| Sex: Female, Male(Participants) | Doravirine 25 mg | Doravirine 200 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 18 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2011 to primary completion in Apr 2012, 5 months.
Results were first posted in Feb 2019, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doravirine